Bernd Buettelmann

This inventor holds 58 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 20 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D). Top assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC. Active years: 2002-2021.

USPTO Granted Patents = 58 (Patent Applications = 2)

% Patents Active = 32.8

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 20 (Patent Applications = 13)

Average Co-Inventor Count = 5.3

ph-index = 7

Forward Citations = 135(Granted Patents)

Forward Citations (Not Self Cited) = 109(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Palo Alto, CA (US) (2010 - 2012)
Schopfheim, DE (2002 - 2017)
Basel, CH (2019 - 2021)

Company Filing History:

52 out of 5,011

Hoffmann-La Roche Inc.

where one patent can have more than one assignee

Years Active: 2002-2021

Loading Chart...

Areas of Expertise:

GABA Modulators

DDR1 Inhibitors

JNK Inhibitors

Isoxazolyl Derivatives

Spiroindolinones

Urea Derivatives

Imidazole Derivatives

Pyridine Derivatives

Thiazole Derivatives

Dihydroquinone

Fatty-Acid Binding Proteins

Aryl Compounds

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11091471 - Isoxazolyl ether derivatives as GABAα5 PAM (2021-08-17),

2. 10618897 - Spiroindolinones as DDR1 inhibitors (2020-04-14),

3. 10435407 - Triaza-spirodecanones as DDR1 inhibitors (2019-10-08),

4. 10239876 - Triaza-spirodecanones as DDR1 inhibitors (2019-03-26),

5. 9708340 - Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors (2017-07-18),

6. 9656971 - COMT inhibitors (2017-05-23),

7. 9604977 - Bicyclic thiophenylamide compounds (2017-03-28),

8. 9562052 - Bicyclicpyridine derivatives (2017-02-07),

9. 9353102 - Non-annulated thiophenylamides (2016-05-31),

10. 9278918 - Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors (2016-03-08),

11. 9073908 - Isoxazolo-pyridine derivatives (2015-07-07),

12. 8877783 - Isoxazolo-pyridine derivatives (2014-11-04),

13. 8877782 - Isoxazolo-pyridine derivatives (2014-11-04),

14. 8846719 - Isoxazolo-pyridine derivatives (2014-09-30),

15. 8569306 - JNK modulators (2013-10-29),

Title: Innovations and Contributions of Bernd Buettelmann

Introduction: Bernd Buettelmann, an accomplished inventor based in Schopfheim, Germany, has made significant contributions to the field of medicinal chemistry and pharmacology. With an impressive portfolio of 58 patents, his work has played a crucial role in the development of new therapeutic compounds.

Latest Patents: One of Buettelmann's recent patents includes the discovery of Isoxazolyl ether derivatives as GABAα5 Positive Allosteric Modulators. This invention consists of compounds having a specific formula, where R, R, R, R, R, R, X, Y, and Z are defined within the patent description, along with compositions and methods of utilizing these compounds for therapeutic applications. Another notable patent is related to Spiroindolinones as DDR1 inhibitors. This invention involves specific compounds aimed at inhibiting DDR1, outlined in the patent's formula.

Career Highlights: Bernd Buettelmann has had a notable career with valuable experience at renowned pharmaceutical companies. He has worked with Hoffmann-La Roche Inc. and Roche Palo Alto LLC, where he has collaborated on various innovative projects that have contributed to advancements in medicine.

Collaborations: Throughout his career, Buettelmann has worked alongside talented professionals, including Andrew William Thomas and Henner Knust. These collaborations have fostered a dynamic research environment, leading to groundbreaking inventions and innovations in the pharmaceutical field.

Conclusion: Bernd Buettelmann's contributions to the field of pharmaceuticals through his numerous patents showcase his dedication to innovation and invention. His work continues to influence the development of new therapeutic compounds, making significant strides in improving healthcare outcomes.